ABBV
AbbVie Inc.Evidence as of 2026-09-12The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ABBV
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic derm…
Management team
- Mr. Jeffrey Ryan Stewart · Executive VP & Chief Commercial OfficerFind on LinkedIn
- Mr. Timothy J. Richmond · Executive VP & Chief Human Resources OfficerFind on LinkedIn
- Dr. Azita Saleki-Gerhardt Ph.D. · Executive VP & COOFind on LinkedIn
- Mr. Scott T. Reents · Executive VP & CFOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The surviving evidence gives a mixed picture. Reported revenues rose from 13,343,000,000 USD in the fiscal quarter ended 31 March 2025 to 16,990,000,000 USD in the fiscal quarter ended 30 June 2026, while operating income increased across comparable quarters from 3,733,000,000 USD (31 March 2025) to 6,432,000,000 USD (30 June 2026), expanding the calculated operating margin from about 28.0% to about 37.9%. Diluted EPS varied materially — 0.72 USD (31 March 2025), 0.52 USD (30 June 2025) and 2.03 USD (30 June 2026) — and cash and cash equivalents declined by 2,822,000,000 USD between 31 March 2026 and 30 June 2026.
Market signals are mixed as well: momentum measures over 3 and 6 months are positive ( +14.4% and +15.0%), a golden cross is intact, volatility sits above historical percentiles, trailing twelve-month FCF is 12,829,000,000 USD (FCF per share 7.2439 ), and reported P/E (TTM) is 72.63 with price per share 257.12 USD as of 2026-09-11. Filings show ongoing deal activity (an 8‑K for the Apogee acquisition on 2026-09-03) and expanded risk language around pricing pressure and concentrated revenue (Skyrizi and Rinvoq together ~ 42% of 2025 revenues).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Reported revenues rose from 13,343,000,000 USD in the fiscal quarter ended 31 March 2025 to 16,990,000,000 USD in the fiscal quarter ended 30 June 2026.
XBRL companyfacts · 0001551152-26-000017Operating income increased across comparable quarters: 3,733,000,000 USD in the quarter ended 31 March 2025, 4,894,000,000 USD in the quarter ended 30 June 2025, and 6,432,000,000 USD in the quarter ended 30 June 2026.
XBRL companyfacts · 0001551152-26-000017Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
AbbVie filed a Current Report on Form 8-K on 2026-09-03 announcing the completion of its acquisition of Apogee Therapeutics, Inc.
8-K filed 2026-09-03The 8-K filed 2026-09-03 includes management language identifying forward-looking statements, including references to AbbVie's 2026 full-year and third-quarter adjusted diluted EPS guidance and anticipated benefits and integration risks related to the Apogee acquisition.
8-K filed 2026-09-03Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the past 3 months is +14.4% as of 2026-09-11 and momentum over the past 6 months is +15.0%.
Moneyta signal set · 2026-09-11weakened in debateThe 12-1 momentum signal is +28.2% (66th percentile of 558) as of 2026-09-11, placing the stock above roughly two-thirds of the research universe on that metric.
Moneyta signal set · 2026-09-11weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F holdings reported a total value of $276.96B as of 2026-03-31, with 4,059 filing holders and a net holder_count change of -87 quarter-over-quarter.
13F holdings · 4059 filers · as of 2026-03-31Top institutional holders reported include BlackRock, Inc. at $32.79B (value_qoq_pct -5.1), VANGUARD CAPITAL MANAGEMENT LLC at $24.99B (new position in the reporting quarter), and STATE STREET CORP at $17.66B (value_qoq_pct -4.5), per the 13F as of 2026-03-31.
13F holdings · 4059 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A headline on 2026-09-11 highlights AbbVie's atogepant meeting its endpoint in a late-stage menstrual migraine study, framing this as a positive data result for the drug program.
News · finance.yahoo.com · 2026-09-11A separate outlet carried the same atogepant headline on 2026-09-11, indicating the trial result was syndicated or picked up by multiple distinct outlets.
News · zacks.com · 2026-09-11Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
On 2026-08-14, Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) reported an open-market-style filing with 'code M' for 32,710 shares valued at "$2.6M" (file shows 32,710 shares and "$2.6M" as the transaction value).
Form 4 · Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) · $2.6M code M · 2026-08-14weakened in debateOn 2026-08-14, Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) reported a sale of 32,710 shares with a reported value of "$8.2M" in the same filing.
Form 4 · Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) · $2.6M code M · 2026-08-14weakened in debateReads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 23.57% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeweakened in debateTrailing twelve-month free cash flow (FCF) is $12,829,000,000 and FCF per share is $7.2439 as of the stated reporting windows.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence set shows multiple company-specific operating and market signals that support a favorable read. Revenues, operating income, and operating margin have meaningfully expanded across the reported quarters (fundamentals-0, fundamentals-1, fundamentals-2), and six-month reporting shows strong net revenues, operating earnings and operating cash flow (filings-2) which together indicate improving core profitability and cash generation. Positive clinical news for atogepant (news-0, news-1), a recent acquisition closing (filings-0), steady dividend declarations (news-2) and meaningful ETF weights in healthcare and dividend-focused funds (ownership-3) align with investor interest and institutional placement that can support valuation sentiment. Market momentum signals (market-0, market-1, market-2) and a low beta (market-6) further show the stock has been gaining relative market traction while exhibiting defensive correlation characteristics.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.30
51 surviving claims rest on 29 distinct sources; the heaviest analyst carries 26% of them, and 95% of what the desk raised survived the debate.
The evidence set is reasonably dense — 51 surviving claims drawn from 29 distinct sources means multiple data points back many assertions, and the 95% survival rate suggests the desk’s checks preserved most items through debate. However, a single analyst accounting for 26% of the surviving claims creates a non-trivial analyst-concentration risk, and the modest source count relative to claim count implies some claims rely on the same underlying documents; treat the read as informational but somewhat fragile to a single-source or single-analyst correction.
Peer context · computed, not argued
12-1 momentum ranks 7th of 10 in Drug Manufacturers—General (as of 2026-09-11).
90-day volatility ranks 7th of 10 in Drug Manufacturers—General (as of 2026-09-11).
dividend yield ranks 5th of 10 in Drug Manufacturers—General (as of 2026-09-11).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
13 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.3 to the score
11 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.4 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.5 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
12 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot−0.1 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on ABBV Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.